Nautilus Biotechnology Stock Performance
| NAUT Stock | USD 2.24 0.06 2.61% |
The company secures a Beta (Market Risk) of 2.44, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nautilus Biotechnology will likely underperform. At this point, Nautilus Biotechnology has a negative expected return of -0.12%. Please make sure to verify Nautilus Biotechnology's value at risk and rate of daily change , to decide if Nautilus Biotechnology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nautilus Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (2.61) | Five Day Return (0.44) | Year To Date Return (25.83) | Ten Year Return (78.54) | All Time Return (78.54) |
1 | Insider Trading | 09/16/2024 |
2 | Disposition of 35000 shares by Mary Godwin of Nautilus Biotechnology at 2.8534 subject to Rule 16b-3 | 09/17/2024 |
3 | Acquisition by Sujal Patel of 41654 shares of Nautilus Biotechnology at 2.9204 subject to Rule 16b-3 | 09/18/2024 |
4 | Disposition of 47031 shares by Mary Godwin of Nautilus Biotechnology at 2.865 subject to Rule 16b-3 | 09/23/2024 |
5 | Nautilus Biotechnology senior VP sells over 134k in company stock - Investing.com | 09/25/2024 |
6 | Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3 | 10/25/2024 |
7 | Nautilus Biotechnology Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 10/30/2024 |
8 | 3 US Penny Stocks With Market Caps Up To 400M | 11/07/2024 |
9 | Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3 | 11/08/2024 |
10 | Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 115.5 M |
Nautilus |
Nautilus Biotechnology Relative Risk vs. Return Landscape
If you would invest 254.00 in Nautilus Biotechnology on September 3, 2024 and sell it today you would lose (30.00) from holding Nautilus Biotechnology or give up 11.81% of portfolio value over 90 days. Nautilus Biotechnology is currently does not generate positive expected returns and assumes 3.9449% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Nautilus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nautilus Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nautilus Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nautilus Biotechnology, and traders can use it to determine the average amount a Nautilus Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NAUT |
Estimated Market Risk
| 3.94 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nautilus Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nautilus Biotechnology by adding Nautilus Biotechnology to a well-diversified portfolio.
Nautilus Biotechnology Fundamentals Growth
Nautilus Stock prices reflect investors' perceptions of the future prospects and financial health of Nautilus Biotechnology, and Nautilus Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nautilus Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.18 | ||||
| Current Valuation | 172.22 M | ||||
| Shares Outstanding | 125.56 M | ||||
| Price To Book | 1.26 X | ||||
| EBITDA | (74.3 M) | ||||
| Net Income | (63.67 M) | ||||
| Cash And Equivalents | 299.34 M | ||||
| Cash Per Share | 2.40 X | ||||
| Total Debt | 34.63 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 49.75 X | ||||
| Book Value Per Share | 1.78 X | ||||
| Cash Flow From Operations | (51.71 M) | ||||
| Earnings Per Share | (0.56) X | ||||
| Market Capitalization | 288.8 M | ||||
| Total Asset | 305.56 M | ||||
| Retained Earnings | (202.24 M) | ||||
| Working Capital | 167.72 M | ||||
About Nautilus Biotechnology Performance
Assessing Nautilus Biotechnology's fundamental ratios provides investors with valuable insights into Nautilus Biotechnology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Nautilus Biotechnology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.21) | (0.20) | |
| Return On Equity | (0.24) | (0.23) |
Things to note about Nautilus Biotechnology performance evaluation
Checking the ongoing alerts about Nautilus Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nautilus Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nautilus Biotechnology generated a negative expected return over the last 90 days | |
| Nautilus Biotechnology has high historical volatility and very poor performance | |
| Net Loss for the year was (63.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nautilus Biotechnology currently holds about 299.34 M in cash with (51.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nautilus Biotechnology has a poor financial position based on the latest SEC disclosures | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: 3 US Penny Stocks With Market Caps Up To 400M |
- Analyzing Nautilus Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nautilus Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Nautilus Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nautilus Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nautilus Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nautilus Biotechnology's stock. These opinions can provide insight into Nautilus Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.